• To compare analgesia in subjects receiving celecoxib versus placebo [ Time Frame: throughout 10 days post-operative ] [ Designated as safety issue: No ]
  

• To compare the incidence of post-operative hemorrhage in subjects receiving celecoxib versus placebo [ Time Frame: operative and 10 days post-operative ] [ Designated as safety issue: Yes ]
  
• To compare the number of days of leave from work or school that subjects need in the postoperative period in subjects receiving celecoxib versus placebo [ Time Frame: 3 weeks post-operatively ] [ Designated as safety issue: No ]
  

Post-tonsillectomy pain is typically controlled through narcotic medications, such as Lortab elixir. Despite its standard use, this pain control is typically not as effective as a non-steroidal anti-inflammatory medication (NSAID). The problem with using NSAIDs for post-tonsillectomy operative pain is the significant increased risk of rebleeding.

Celecoxib is an NSAID that is a COX-2 inhibitor; the drug is designed to act as an NSAID without the increased risk of rebleeding or hemorrhage.

This study is a double blind, randomized study; neither the study participant or the study investigator knows if the participant is receiving celecoxib or a placebo (sugar pill). The blinded list is maintained by the research pharmacists and can be unblinded when needed (such as in an emergency).

Participants begin taking the study medication the night before surgery and continue through 10 days post-operative. Participants are asked to complete a journal that catalogs the amount of standard post-operative medications taken, the amount of pain experienced, and any other comments.

Participants are contacted by phone at 5 and 10 days post-op.

Study participation ends at the standard 3-week post-operative check-up.